Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
REGULATORY
Japan to Revise PMD Law to Create Emergency Approval System, Final Paper Due Out by Year-End
The Japanese government is now set to create an emergency approval system based on “presumed efficacy,” with a health ministry panel giving the thumbs-up on December 22 to a paper paving the way for a legal amendment to this effect.…
To read the full story
Related Article
- MHLW Panel Urges Better Application of Emergency Approval
January 16, 2023
- LDP Lawmakers Want Specific Definitions for Emergency Approval Prerequisites
January 18, 2022
- Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
January 17, 2022
- Govt to Submit PMD Law Amendment Bill in Ordinary Diet Session to Introduce Emergency Approval
January 7, 2022
- MHLW Finalizes Paper on Emergency Approval System, Set to Submit Bill Next Year
December 28, 2021
- Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
- MHLW Eyes Emergency Approval System Based on “Presumed” Efficacy
December 2, 2021
- Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
REGULATORY
- Suprapartisan Lawmakers’ League Discussing Bill to Establish Dementia Law
March 31, 2023
- LDP League Asks Health Minster for Proper Insurance Coverage for Patches
March 31, 2023
- AMED’s “CANNDs” Set for Full Rollout in FY2023, but Panel Members Want Wider Range of Data to Fuel Drug Discovery
March 31, 2023
- Audit Questions Rationale for Order of 882 Million COVID Vaccine Doses
March 30, 2023
- Japan to Allow Drone Deliveries of Drugs When Appropriate, Including Powerful Meds
March 29, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…